66 related articles for article (PubMed ID: 25810324)
1. Postgastrectomy pharmacokinetic changes of S-1 in patients with localized advanced gastric cancer.
Lim HS; Ryu KW; Lee JH; Kim YW; Ju Choi I; Kim MJ; Park YI; Hwang A; Park SR
J Clin Pharmacol; 2015 Aug; 55(8):926-35. PubMed ID: 25810324
[TBL] [Abstract][Full Text] [Related]
2. CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.
Fujita K; Yamamoto W; Endo S; Endo H; Nagashima F; Ichikawa W; Tanaka R; Miya T; Araki K; Kodama K; Sunakawa Y; Narabayashi M; Miwa K; Ando Y; Akiyama Y; Kawara K; Kamataki T; Sasaki Y
Cancer Sci; 2008 May; 99(5):1049-54. PubMed ID: 18380793
[TBL] [Abstract][Full Text] [Related]
3. Alternative pharmacokinetics of S-1 components, 5-fluorouracil, dihydrofluorouracil and alpha-fluoro-beta-alanine after oral administration of S-1 following total gastrectomy.
Kim WY; Nakata B; Hirakawa K
Cancer Sci; 2007 Oct; 98(10):1604-8. PubMed ID: 17683513
[TBL] [Abstract][Full Text] [Related]
4. Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study.
Booka E; Imamura CK; Takeuchi H; Hamamoto Y; Gomi D; Mizukami T; Ichiyama T; Tateishi K; Takahashi T; Kawakubo H; Soejima K; Boku N; Tanigawara Y; Kitagawa Y
Gastric Cancer; 2016 Jul; 19(3):876-86. PubMed ID: 26304171
[TBL] [Abstract][Full Text] [Related]
5. Practical Consensus Guidelines for the Use of S-1 in GI Malignancies.
Parikh PM; Sahoo TP; Biswas G; Talwar V; Sp S; Panda SS; Cb A; Shetty N; Ramesh A; Ghosh J; Shetty VV; Naik R; Singh A; Gupta G; Parekh B
South Asian J Cancer; 2024 Jan; 13(1):77-82. PubMed ID: 38721104
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for discontinuation of s-1 adjuvant chemotherapy for gastric cancer.
Kawazoe H; Shimasaki M; Ueno M; Sumikawa S; Takatori S; Namba H; Yoshida M; Sato K; Kojima Y; Watanabe Y; Moriguchi T; Tanaka A; Araki H
J Cancer; 2015; 6(5):464-9. PubMed ID: 25874010
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival.
Kim YW; Kim MJ; Ryu KW; Lim HS; Lee JH; Kong SY; Lee JS; Choi IJ; Kim CG; Lee JY; Cho SJ; Kook MC; Park YI; Kim SK; Park SR
Gastric Cancer; 2016 Apr; 19(2):586-596. PubMed ID: 25851942
[TBL] [Abstract][Full Text] [Related]
8. FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study.
Iwamoto S; Takahashi T; Tamagawa H; Nakamura M; Munemoto Y; Kato T; Hata T; Denda T; Morita Y; Inukai M; Kunieda K; Nagata N; Kurachi K; Ina K; Ooshiro M; Shimoyama T; Baba H; Oba K; Sakamoto J; Mishima H
Ann Oncol; 2015 Jul; 26(7):1427-33. PubMed ID: 25908603
[TBL] [Abstract][Full Text] [Related]
9. Preoperative systemic and intraperitoneal chemotherapy consisting of S-1, cisplatin and docetaxel in patients with marginally resectable gastric cancer.
Kurokawa Y; Hamakawa T; Miyazaki Y; Takahashi T; Yamasaki M; Miyata H; Nakajima K; Takiguchi S; Mori M; Doki Y
Anticancer Res; 2015 Apr; 35(4):2223-8. PubMed ID: 25862882
[TBL] [Abstract][Full Text] [Related]
10. Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX.
Peixoto RD; Ho M; Renouf DJ; Lim HJ; Gill S; Ruan JY; Cheung WY
Am J Clin Oncol; 2017 Oct; 40(5):507-511. PubMed ID: 25844823
[TBL] [Abstract][Full Text] [Related]
11. Randomized clinical trial of adjuvant chemotherapy with S-1 versus gemcitabine after pancreatic cancer resection.
Shimoda M; Kubota K; Shimizu T; Katoh M
Br J Surg; 2015 Jun; 102(7):746-54. PubMed ID: 25833230
[TBL] [Abstract][Full Text] [Related]
12. Safety and feasibility of S-1 adjuvant chemotherapy for pancreatic cancer in elderly patients.
Aoyama T; Katayama Y; Murakawa M; Atsumi Y; Yamaoku K; Kanazawa A; Higuchi A; Shiozawa M; Kobayashi S; Ueno M; Morimoto M; Yamamoto N; Oshima T; Yoshikawa T; Rino Y; Masuda M; Morinaga S
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1115-20. PubMed ID: 25821166
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of S-1 vs capecitabine for the treatment of gastric cancer: a meta-analysis.
He AB; Peng XL; Song J; Zhang JX; Dong WG; Luo RF; Tang Y
World J Gastroenterol; 2015 Apr; 21(14):4358-64. PubMed ID: 25892887
[TBL] [Abstract][Full Text] [Related]
14. Nanoparticle albumin-bound-paclitaxel: a limited improvement under the current therapeutic paradigm of pancreatic cancer.
Hoffman RM; Bouvet M
Expert Opin Pharmacother; 2015 May; 16(7):943-7. PubMed ID: 25887245
[TBL] [Abstract][Full Text] [Related]
15. Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility study.
Shigekawa T; Osaki A; Sekine H; Sato N; Kanbayashi C; Sano H; Takeuchi H; Ueda S; Nakamiya N; Sugitani I; Sugiyama M; Shimada H; Hirokawa E; Takahashi T; Saeki T
BMC Cancer; 2015 Apr; 15():253. PubMed ID: 25884795
[TBL] [Abstract][Full Text] [Related]
16. A Meta-analysis Reveals S-1-based Chemotherapy Improves the Survival of Patients With Advanced Gastric Cancer.
Wu FL; Lu DC; Ying YP; Huang JJ; Zhou AM; Jiang DK; Chen MW; Yang X; Zhou J; Huang HQ; Zeng HY
Medicine (Baltimore); 2015 Apr; 94(16):e652. PubMed ID: 25906091
[TBL] [Abstract][Full Text] [Related]
17. Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2'-deoxy-5-fluorouridine into DNA.
Sakamoto K; Yokogawa T; Ueno H; Oguchi K; Kazuno H; Ishida K; Tanaka N; Osada A; Yamada Y; Okabe H; Matsuo K
Int J Oncol; 2015; 46(6):2327-34. PubMed ID: 25901475
[TBL] [Abstract][Full Text] [Related]
18. Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron.
Komatsu Y; Okita K; Yuki S; Furuhata T; Fukushima H; Masuko H; Kawamoto Y; Isobe H; Miyagishima T; Sasaki K; Nakamura M; Ohsaki Y; Nakajima J; Tateyama M; Eto K; Minami S; Yokoyama R; Iwanaga I; Shibuya H; Kudo M; Oba K; Takahashi Y
Cancer Sci; 2015 Jul; 106(7):891-5. PubMed ID: 25872578
[TBL] [Abstract][Full Text] [Related]
19. Randomized study of orally administered fluorinated pyrimidines (capecitabine versus S-1) in women with metastatic or recurrent breast cancer: Japan Breast Cancer Research Network 05 Trial.
Yamamoto D; Iwase S; Tsubota Y; Ariyoshi K; Kawaguchi T; Miyaji T; Sueoka N; Yamamoto C; Teramoto S; Odagiri H; Kitamura K; Nagumo Y; Yamaguchi T
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1183-9. PubMed ID: 25862350
[TBL] [Abstract][Full Text] [Related]
20. Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial).
Yoshida M; Muro K; Tsuji A; Hamamoto Y; Yoshino T; Yoshida K; Shirao K; Miyata Y; Takahari D; Takahashi T; Ohtsu A
Eur J Cancer; 2015 May; 51(8):935-41. PubMed ID: 25837882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
